Statin administration or blocking PCSK9 alleviates airway hyperresponsiveness and lung fibrosis in high-fat diet-induced obese mice
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Lipid-lowering drugs like statins and alirocumab can reduce obesity-related airway hyperresponsiveness and lung fibrosis. These treatments target inflammation and fibrotic pathways, offering potential benefits for asthma patients with obesity.
Area Of Science
- Pulmonary Medicine
- Cardiovascular Pharmacology
Background
- Obesity exacerbates airway hyperresponsiveness and lung fibrosis, complicating asthma management.
- Statins and PCSK9 inhibitors lower lipids and possess anti-inflammatory and renin-angiotensin system-inhibiting properties.
Purpose Of The Study
- To investigate the effects of atorvastatin and alirocumab on obesity-induced airway hyperresponsiveness and lung fibrosis.
- To explore the impact of these lipid-lowering agents on inflammatory and fibrotic pathways in the lungs.
Main Methods
- Obesity was induced in C57BL/6 mice using a high-fat diet.
- Mice received atorvastatin or alirocumab to assess effects on airway hyperresponsiveness and lung pathology.
Main Results
- Obesity increased airway hyperresponsiveness, lung fibrosis, and pro-inflammatory mediators.
- Atorvastatin and alirocumab attenuated these markers, reduced serum leptin and free fatty acids, and inhibited TGF-β1, IL-1β, IL-6, and IL-17a.
- These agents also reduced renin-angiotensin system (RAS), NLRP3 inflammasome, and cholecystokinin activity in lung tissue.
Conclusions
- Lipid-lowering therapy shows potential in mitigating obesity-associated airway hyperresponsiveness and lung fibrosis.
- Inhibition of NLRP3 inflammasome, RAS, and cholecystokinin activity are key mechanisms.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.